Home › Funds › ADAR1 Capital Management, LLC › JANX

ADAR1 Capital Management, LLC position in JANX

JANUX THERAPEUTICS INC · Health Care

ADAR1 Capital Management, LLC reported holding 823,876 shares of JANX (JANUX THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$14.2M, representing 0.78% of its reported portfolio and ranking #31 among its reported holdings. ADAR1 Capital Management, LLC has disclosed JANX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)823.88K sh
Reported value held$14.24M
Portfolio Weight0.78%
First reportedQ1 2024
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How ADAR1 Capital Management, LLC's JANX position evolved

ADAR1 Capital Management, LLC first disclosed a stake in JANX in Q1 2024 at 14,000 shares (US$527K). The position peaked in Q3 2026 at 823,876 shares, worth US$14.2M. Across 11 filings, ADAR1 Capital Management, LLC increased the stake 7 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 823,876 shares valued at US$14.2M — an increase of 402,995 shares quarter over quarter.. Notable position changes include a 142% increase in Q4 2024 (shares fell 50% over the following quarter), a 388% increase in Q1 2025 (shares fell 14% over the following quarter), a 465% increase in Q3 2025 (shares fell 44% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 14.00K $527.10K New
Q2 2024 7.89K $330.55K Reduce
Q3 2024 13.00K $590.59K Add
Q4 2024 31.51K $1.69M Add
Q1 2025 153.77K $4.15M Add
Q2 2025 62.09K $1.43M Reduce
Q3 2025 351.03K $8.58M Add
Q4 2025 245.45K $3.39M Reduce
Q1 2026 298.55K $4.15M Add
Q2 2026 420.88K $6.46M Add
Q3 2026 823.88K $14.24M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JANX and 13F data

JANX (JANUX THERAPEUTICS INC) is a Health Care company. 27 other funds we track also report a position in JANX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$171.9M), Prosight Management, LP (US$50.9M), TCG Crossover Management, LLC (US$30.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JANX

All JANX fund holders →

FAQ

How long has ADAR1 Capital Management, LLC held JANX?

ADAR1 Capital Management, LLC has disclosed JANX holdings in 11 of the last 11 reported quarters, going back to Q1 2024.

What is ADAR1 Capital Management, LLC's current position in JANX?

As of Q3 2026, ADAR1 Capital Management, LLC holds 823.88K shares of JANX (JANUX THERAPEUTICS INC), valued at $14.24M, representing 0.78% of its reported portfolio and ranking #31.

Has ADAR1 Capital Management, LLC been buying or selling JANX?

In the latest 13F filing (Q3 2026), ADAR1 Capital Management, LLC increased its position in JANX. The position peaked in Q3 2026 at 823.88K shares.

Which other funds hold JANX?

Other major institutional holders of JANX include RA CAPITAL MANAGEMENT, L.P., Prosight Management, LP, TCG Crossover Management, LLC, among 27 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.